4-iodo-2,5-dimethoxyphenylisopropylamine has been researched along with Benign Neoplasms in 1 studies
4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist
2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dolusić, E | 1 |
| Larrieu, P | 1 |
| Moineaux, L | 1 |
| Stroobant, V | 1 |
| Pilotte, L | 1 |
| Colau, D | 1 |
| Pochet, L | 1 |
| Van den Eynde, B | 1 |
| Masereel, B | 1 |
| Wouters, J | 1 |
| Frédérick, R | 1 |
1 other study available for 4-iodo-2,5-dimethoxyphenylisopropylamine and Benign Neoplasms
| Article | Year |
|---|---|
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line; Drug Design; Enzyme Inhibitors; | 2011 |